BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7536027)

  • 1. Secondary tumours following etoposide containing therapy for germ cell cancer.
    Boshoff C; Begent RH; Oliver RT; Rustin GJ; Newlands ES; Andrews R; Skelton M; Holden L; Ong J
    Ann Oncol; 1995 Jan; 6(1):35-40. PubMed ID: 7536027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.
    Bower M; Newlands ES; Holden L; Rustin GJ; Begent RH
    Ann Oncol; 1997 May; 8(5):477-83. PubMed ID: 9233528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime.
    Cullen MH; Harper PG; Woodroffe CM; Kirkbride P; Clarke J
    Br J Urol; 1988 Nov; 62(5):454-60. PubMed ID: 2463034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
    Kollmannsberger C; Beyer J; Droz JP; Harstrick A; Hartmann JT; Biron P; Fléchon A; Schöffski P; Kuczyk M; Schmoll HJ; Kanz L; Bokemeyer C
    J Clin Oncol; 1998 Oct; 16(10):3386-91. PubMed ID: 9779717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy.
    Bajorin DF; Motzer RJ; Rodriguez E; Murphy B; Bosl GJ
    J Natl Cancer Inst; 1993 Jan; 85(1):60-2. PubMed ID: 7677936
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy for ovarian germ cell tumours.
    Bower M; Fife K; Holden L; Paradinas FJ; Rustin GJ; Newlands ES
    Eur J Cancer; 1996 Apr; 32A(4):593-7. PubMed ID: 8695258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The chemotherapy of nonseminomatous testicular tumors].
    Tiuliandin SA; Bulanov AA; Titov DA; Sokolov AV; Sholokhov VN; Garin AM
    Urol Nefrol (Mosk); 1996; (2):26-9. PubMed ID: 8677548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity.
    Husband DJ; Green JA
    Eur J Cancer; 1992; 28(1):86-91. PubMed ID: 1373636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours.
    Pedersen-Bjergaard J; Daugaard G; Hansen SW; Philip P; Larsen SO; Rørth M
    Lancet; 1991 Aug; 338(8763):359-63. PubMed ID: 1713639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. POMB/ACE chemotherapy for mediastinal germ-cell tumours.
    Droz JP
    Eur J Cancer; 1997 May; 33(6):809-11. PubMed ID: 9291797
    [No Abstract]   [Full Text] [Related]  

  • 12. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols.
    Nichols CR; Breeden ES; Loehrer PJ; Williams SD; Einhorn LH
    J Natl Cancer Inst; 1993 Jan; 85(1):36-40. PubMed ID: 7677934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours.
    Ledermann JA; Holden L; Newlands ES; Begent RH; Rustin GJ; Bagshawe KD; Brampton M
    Br J Urol; 1994 Aug; 74(2):225-30. PubMed ID: 7522874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for non-seminomatous germ-cell tumours.
    Wilkinson PM
    J R Soc Med; 1985; 78 Suppl 6(Suppl 6):43-7. PubMed ID: 2582119
    [No Abstract]   [Full Text] [Related]  

  • 15. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
    Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
    Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
    Wierecky J; Kollmannsberger C; Boehlke I; Kuczyk M; Schleicher J; Schleucher N; Metzner B; Kanz L; Hartmann JT; Bokemeyer C
    J Cancer Res Clin Oncol; 2005 Apr; 131(4):255-60. PubMed ID: 15627215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the Australasian Germ Cell Trial Group: the management of advanced testis cancer.
    Raghavan D; Levi J; Thomson D; Harvey V
    Prog Clin Biol Res; 1990; 350():319-29. PubMed ID: 1696742
    [No Abstract]   [Full Text] [Related]  

  • 18. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
    Mann JR; Raafat F; Robinson K; Imeson J; Gornall P; Sokal M; Gray E; McKeever P; Hale J; Bailey S; Oakhill A
    J Clin Oncol; 2000 Nov; 18(22):3809-18. PubMed ID: 11078494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause.
    Savage P; Cooke R; O'Nions J; Krell J; Kwan A; Camarata M; Dancy G; Short D; Seckl MJ; Swerdlow A
    J Clin Oncol; 2015 Feb; 33(5):472-8. PubMed ID: 25547507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of testicular cancer and the development of secondary malignancies.
    Bokemeyer C; Schmoll HJ
    J Clin Oncol; 1995 Jan; 13(1):283-92. PubMed ID: 7799032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.